Want to see CALC full AI Analyst Report?
Top Page
CalciMedica
(NASDAQ:CALC)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▲(154.24% Upside)
Action:Reiterated
Date:09/30/26
The score is primarily weighed down by weak financial performance (pre-revenue, ongoing losses and cash burn) and bearish technicals (price below key moving averages with negative momentum). Corporate actions modestly offset this by improving listing stability, but the ATM and equity-related measures point to continued reliance on equity financing, while valuation metrics offer limited support due to negative earnings.
Positive Factors
Low leverage
The absence of debt reduces near-term leverage and interest-burden risk, giving CalciMedica greater flexibility while it funds clinical development. Positive equity also provides a stronger base than prior periods with negative equity, although continued losses remain a constraint.
Negative Factors
No commercial revenue
The absence of revenue means CalciMedica has not yet demonstrated commercial demand or a self-funding business model. Persistent operating losses leave future progress dependent on successful development, regulatory execution, and eventual product commercialization rather than established recurring sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
The absence of debt reduces near-term leverage and interest-burden risk, giving CalciMedica greater flexibility while it funds clinical development. Positive equity also provides a stronger base than prior periods with negative equity, although continued losses remain a constraint.
Read all positive factors
CalciMedica (CALC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.93M
Dividend YieldN/A
Average Volume (3M)81.37K
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue GrowthN/A
EPS Growth15.37%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.90
Shares Outstanding6,828,292
10 Day Avg. Volume46,836
30 Day Avg. Volume81,371
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-14.90K
Price to Sales (P/S)0.00
P/FCF Ratio-4.66K
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.17K
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$9.00Price Target Upside1425.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.3
Revenue Forecast (FY)N/A
CalciMedica Business Overview & Revenue Model
Company Description
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approac...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, CalciMedica does not have publicly established recurring product revenue from commercialized drugs. Its funding and cash inflows are therefore primarily driven by external financing and, when applicab...
CalciMedica Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -7.00K | -46.00K | 0.00 | 0.00 | 0.00 | -519.00K |
| EBITDA | -19.91M | -28.09M | -13.64M | -34.19M | -7.64M | -35.30M |
| Net Income | -21.24M | -29.56M | -13.70M | -34.36M | -7.82M | -35.82M |
Balance Sheet | ||||||
| Total Assets | 19.50M | 13.59M | 19.79M | 12.19M | 3.35M | 69.09M |
| Cash, Cash Equivalents and Short-Term Investments | 18.62M | 13.02M | 18.67M | 11.24M | 1.33M | 63.67M |
| Total Debt | 0.00 | 9.70M | 0.00 | 0.00 | 5.36M | 0.00 |
| Total Liabilities | 13.99M | 20.23M | 5.38M | 4.03M | 12.58M | 4.07M |
| Stockholders Equity | 5.51M | -6.64M | 14.41M | 8.16M | -9.23M | 65.02M |
Cash Flow | ||||||
| Free Cash Flow | -19.12M | -21.21M | -21.15M | -25.81M | -11.76M | -31.99M |
| Operating Cash Flow | -19.11M | -21.18M | -21.15M | -25.73M | -11.76M | -31.50M |
| Investing Cash Flow | 12.20M | 9.55M | -4.42M | 8.88M | -4.00K | 10.75M |
| Financing Cash Flow | 19.60M | 15.21M | 27.97M | 20.90M | 8.48M | 695.00K |
CalciMedica Technical Analysis
Negative
0.59
Price Trends
2.67
Negative
3.35
Negative
6.81
Negative
Market Momentum
-0.29
Negative
28.42
Positive
10.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CALC, the sentiment is Negative. The current price of 0.59 is below the 20-day moving average (MA) of 1.88, below the 50-day MA of 2.67, and below the 200-day MA of 6.81, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 28.42 is Positive, neither overbought nor oversold. The STOCH value of 10.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CALC.
CalciMedica Risk Analysis
CalciMedica disclosed 71 risk factors in its most recent earnings report. CalciMedica reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CalciMedica Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $41.89M | -1.17 | -708.20% | ― | ― | 30.16% | |
43 Neutral | $7.44M | -0.17 | -329.08% | ― | ― | -19.07% | |
42 Neutral | $10.93M | -0.23 | 3398.40% | ― | ― | 15.37% | |
41 Neutral | $11.00M | -0.53 | -456.35% | ― | ― | 9.68% | |
41 Neutral | $10.04M | -0.18 | -1539.97% | ― | ― | 80.28% |
* Healthcare Sector Average
CALC
CalciMedica
1.60
-14.65
-90.15%
PDSB
PDS Biotechnology
0.75
-0.21
-22.25%
SKYE
Skye Bioscience
1.68
-13.52
-88.95%
LTRN
Lantern Pharma
0.86
-3.54
-80.45%
SNTI
Senti Biosciences
0.32
-1.35
-80.72%
CalciMedica Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
CalciMedica Establishes $25 Million ATM Stock Program
Positive
Sep 30, 2026
On September 30, 2026, CalciMedica filed a prospectus supplement with the Securities and Exchange Commission to enable sales of up to $25 million of its common stock under an existing at-the-market offering agreement with H.C. Wainwright Co. This...
Delistings and Listing ChangesRegulatory Filings and Compliance
CalciMedica Regains Nasdaq Compliance, Listing Status Stabilized
Positive
Sep 16, 2026
On March 16, 2026, CalciMedica received a notice from Nasdaq that its common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, putting the company out of compliance with Listing Rule 5550(a)(2). The company was g...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and ComplianceStock Split
CalciMedica Addresses Nasdaq Equity Compliance Amid Bid-Price Risk
Negative
Sep 2, 2026
On August 31, 2026, CalciMedica reported that Nasdaq staff determined the company now satisfies the alternative minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), based on its June 30, 2026 Form 10-Q showing $5.513 milli...
Regulatory Filings and ComplianceShareholder MeetingsStock Split
CalciMedica Announces One-for-Five Reverse Stock Split
Neutral
Aug 27, 2026
On August 27, 2026, CalciMedica filed an amendment to its certificate of incorporation in Delaware to implement a one-for-five reverse stock split and reduce its authorized common shares from 500,000,000 to 100,000,000, effective at 5:00 p.m. East...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
CalciMedica Shareholders Approve Key Equity and Governance Changes
Positive
Aug 20, 2026
On August 19, 2026, CalciMedica held its 2026 annual meeting of stockholders, where investors approved an amendment to the 2023 Equity Incentive Plan, increasing available shares by 7,500,000 and broadening the automatic share reserve calculation ...
Executive/Board Changes
CalciMedica Announces Board Expansion and Leadership Transition
Neutral
Jul 7, 2026
On July 2, 2026, CalciMedica’s board of directors expanded from seven to eight seats and appointed Evgeny Zaytsev, M.D., Ph.D., as a Class I director, with his term running until the 2027 annual meeting of stockholders. Zaytsev’s appoi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.